Latest:
Dr. Ueno on Liquid Biopsy
Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Naoto Ueno, MD, PhD, FACP
Latest:
Dr. Ueno on Patient-Reported Outcomes With Trastuzumab Deruxtecan in HR+/HER2-Low Breast Cancer
Naoto T. Ueno, MD, PhD, FACP, discusses patient-reported outcomes with fam-trastuzumab deruxtecan-nxki (Enhertu) in hormone receptor (HR)–positive/HER2-low metastatic breast cancer.
Narendranath Epperla, MBBS, MS
Latest:
Dr. Epperla on the Implications of an FDA Approval for Ublituximab/Umbralisib in CLL
Narendranath Epperla, MD, MS, discusses the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia.
Nate Gosse, PhD
Latest:
Moving to Electronic Prior Authorization Requires Incremental Steps
In a time of tremendous technological advancement, how is it that 90% of communications between providers and payers for prior authorizations are still done by phone or fax, and how do we move to more automated processes?1
Nathan A. Pennell, MD, PhD
Nathan A. Pennell is director of the Cleveland Clinic Lung Cancer Medical Oncology Program and Vice Chair of Clinical Research for the Taussig Cancer Center.
Latest:
Dr Pennell on the Significance of the FDA Approval of Taletrectinib for ROS1+ NSCLC
Nathan A. Pennell, MD, PhD, discusses the significance of the FDA approval of taletrectinib for ROS1-positive non-small cell lung cancer.